News

The FDA has accepted the company’s investigational new drug (IND) application for the phase I/IIa study of TB-403, which is expected to start in the first quarter of

The company said all five patients in the low-dose cohort had Factor IX (FIX) phenotypic features of severe or moderately-severe hemophilia including documented FIX levels less than 1%

The collaborative research agreement with Janssen Biotech and the French National Institute for Agriculture Research (INRA) will focus on the discovery of novel targets and therapeutics for Crohn’s

NCCN, a not-for-profit alliance of 26 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency

In February 2015, the company licensed exclusive, worldwide rights in its adenosine receptor antagonist programme for use in all therapeutic applications to Corvus, a U.S.-based biotechnology company. At

Under the terms of the agreement, X-Chem is applying its discovery engine, which leverages a high diversity, proprietary DNA-encoded small molecule library to seek the identification of novel

The formal authorizations from regulatory agencies in France, Italy and Czech Republic, and the positive opinions from national ethic committees in these three countries enable the initiation of

The selected candidate, ImmTAC, will address a target relevant in several cancer indications such as synovial sarcoma, bladder and non-small cell lung (NSCL) cancers. Immunocore will carry out

The drug had no serious adverse events, bleeding or injection site reactions, the company said. The 59-patient trail has revealed that patients who were given 30 mg and